Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

(2022) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†

(2020) F. Cardoso et al.   ANNALS OF ONCOLOGY

Clinical utility of circulating tumor cells: an update

(2020) Antoine Vasseur et al.   Molecular Oncology

Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

(2020) François-Clément Bidard et al.   JAMA Oncology

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

(2018) F Cardoso et al.   ANNALS OF ONCOLOGY

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

(2014) François-Clément Bidard et al.   LANCET ONCOLOGY